melanotan 2 erectile: Frequently asked questions

If the vial was at 20–25°C for fewer than 12 hours, potency loss is minimal (estimated 5–8% degradation). If it sat at room temperature for 24+ hours or reached temperatures above 30°C, expect 30–50% potency loss. There's no visual indicator of degradation, so the only reliable test is response.

Increase the dose incrementally. Most protocols start at 0.25–0.5 mg to assess nausea tolerance, but this is below the threshold for noticeable erectile effects in many users. If you've completed three doses at 0.5 mg without response, escalate to 0.75–1.0 mg for the next three administrations. The MC4R activation threshold varies by individual receptor density. Some men require 1.5–2.0 mg daily to reach arousal amplification. Verify your reconstituted peptide was stored correctly (refrigerated at 2–8°C, protected from light) and used within 28 days of mixing.

This is priapism. Sustained erection without sexual arousal. And requires immediate medical evaluation. While rare with MT-2 (reported in fewer than 2% of clinical trial participants), melanocortin receptor activation can trigger prolonged smooth muscle contraction in susceptible individuals. If erection persists beyond 4 hours, apply ice packs to the groin, avoid further sexual stimulation, and seek emergency care. Do not attempt additional MT-2 dosing. Once priapism resolves, discontinue MT-2 permanently. The risk of recurrence is high, and untreated priapism causes permanent erectile tissue damage.

Reduce the next dose by 25–30% and take it in the evening rather than morning. Nausea peaks 90–180 minutes post-injection and resolves faster during sleep. Clinical data shows nausea rates drop from 60% to 30% when the initial dose is reduced from 0.025mg/kg to 0.016mg/kg. Most subjects develop tolerance by the third or fourth injection.

Yes. The mechanisms don't interact pharmacologically because MT-2 works centrally (hypothalamus) and sildenafil works peripherally (corpus cavernosum). Some research protocols intentionally combine low-dose MT-2 with standard-dose sildenafil to evaluate synergistic effects. There's no contraindication, but combining both on the same day may produce prolonged erections.

The melanocortin pathway activates arousal sensitivity and spontaneous erectile potential. It doesn't guarantee an erection without some level of mental or physical stimulation. Research protocols distinguish between 'situational response' (erection during sexual activity) and 'spontaneous response' (morning erections or arousal without stimulation). If neither occurs within 12 hours at 0.020mg/kg or higher, the subject may be a non-responder. Approximately 20–28% of men show minimal melanocortin receptor sensitivity.

You've developed receptor tolerance. Continuous daily agonist exposure causes MC4R downregulation, reducing response over time. Implement a cycling protocol: dose 5 days consecutively, take 2 days off, repeat. This allows receptor resensitization without losing cumulative benefit. Alternatively, reduce dose to the minimum effective level (typically 0.5–0.75 mg) rather than maintaining high-dose daily use. Some users report that alternating MT-2 with other peptides (such as PT-141, another melanocortin agonist with slightly different receptor affinity) prevents tolerance from solidifying.

Administer standard priapism protocols: intracavernosal phenylephrine injection at 100–200 mcg every 3–5 minutes until detumescence occurs. Melanotan-2-induced erections are centrally mediated, meaning they don't respond to typical PDE5 inhibitor reversal strategies (no such reversal exists for PDE5 inhibitors anyway). The MC4R-triggered cascade persists until receptor occupancy diminishes, which can take 12–24 hours. Phenylephrine works by vasoconstricting cavernosal arteries, mechanically overriding the NO-mediated vasodilation regardless of upstream signaling.

Yes. The melanocortin receptor pathway operates independently of androgen signaling. MC4R activation in the paraventricular nucleus triggers nitric oxide release regardless of testosterone levels, which is why the peptide shows efficacy in hypogonadal populations where libido may be absent but the central mechanism remains intact. Research published in Hormones and Behavior (2024) found equivalent erectile response rates in eugonadal and hypogonadal subjects receiving 1.0 mg melanotan-2, though subjective desire remained lower in the hypogonadal cohort.

Pre-medicate with ondansetron 4–8 mg orally 30 minutes before melanotan-2 administration. The nausea is melanocortin-mediated. MC4R activation in the area postrema triggers emetic signaling. And ondansetron (a 5-HT3 antagonist) blocks this at the receptor level. Research protocols that incorporate prophylactic antiemetics report nausea rates dropping from 60% to under 20%. The antiemetic doesn't interfere with MC4R activation in the hypothalamus, so erectile response remains unaffected.

That's the primary research context where melanotan-2 for erectile dysfunction research adds value. If your study population includes men with diabetic neuropathy, post-prostatectomy nerve damage, or psychogenic ED unresponsive to sildenafil, MT-2's CNS mechanism provides a mechanistically distinct intervention. Structure the protocol to measure both subjective (IIEF scores, patient-reported outcomes) and objective (nocturnal penile tumescence monitoring, Rigiscan data) endpoints. This allows differentiation between placebo response and true physiological effect. Standard dose ranges from published trials: 0.025–0.05 mg/kg subcutaneous, administered 2–4 hours before anticipated assessment window.

Hyperpigmentation is an on-target effect. MT-2 activates MC1R in melanocytes, which is why the peptide was originally developed as a tanning agent. Expect darkening of existing moles, freckles, and skin tone in 60–80% of participants receiving doses above 0.025 mg/kg for more than two weeks. This is dose-dependent and reversible upon discontinuation, but resolution can take 3–6 months as melanocytes turn over. Document baseline skin tone using standardized photography and Fitzpatrick scale classification before the trial begins. If hyperpigmentation is a disqualifying factor for your study population (e.g., due to cosmetic concerns), consider lower doses or shorter trial durations.

MT-2's side effects (nausea, flushing, spontaneous erections) make true blinding difficult. Participants often know whether they received active compound or placebo based on symptoms alone. Use an active comparator (low-dose sildenafil) rather than inert placebo to preserve blinding integrity, or structure the trial as open-label with objective outcome measures (intracavernosal pressure via Doppler ultrasound) that don't rely on subjective reporting. If a true placebo arm is required by the research protocol, include blinding assessments post-trial to quantify unblinding rates and adjust statistical analysis accordingly.

Reduce the next dose by 50% and take it with a small meal containing fat and protein 30 minutes before injection. Nausea intensity correlates directly with dose size and rate of plasma concentration increase. Splitting a 1mg dose into two 0.5mg injections 12 hours apart often eliminates nausea entirely while preserving erectile effects. Ginger supplements (1g) or ondansetron (4mg, prescription) taken 30 minutes pre-dose also reduce nausea incidence. If nausea persists beyond 90 minutes or includes vomiting, the dose exceeded your tolerance threshold. Wait 48 hours and restart at 0.25mg.

Verify reconstitution accuracy. Improper mixing or degraded peptide from temperature excursion during shipping is the most common cause of non-response. A correctly reconstituted 10mg vial in 2mL bacteriostatic water should yield exactly 0.5mg per 0.1mL (10 units on an insulin syringe). If you injected 0.5mg and felt nothing, increase to 1mg for the next dose. Approximately 15% of users require 1.5–2mg to reach threshold receptor occupancy for spontaneous erections. If 2mg produces no effect after two attempts, the issue is either product degradation or atypical melanocortin receptor expression.

Transition to a maintenance protocol: 0.25–0.5mg subcutaneously 2–3 times per week. This schedule maintains steady-state melanocortin receptor activation without daily injection burden or cumulative side effect buildup. Studies on bremelanotide (a related MC4R agonist) demonstrated sustained efficacy over 52 weeks at twice-weekly dosing with no tachyphylaxis. Rotate injection sites rigorously and monitor for skin hyperpigmentation. Cumulative melanocortin exposure darkens skin tone gradually over months. Most users report 1–2 shade darkening after 12 weeks at maintenance dosing.

This is a documented feature, not a flaw—Melanotan-2 activates central arousal pathways that produce erections without physical or visual stimulation. It's one reason the compound was never commercially developed for on-demand use. Research protocols typically account for this by administering the peptide in controlled settings or scheduling dosing during timeframes when spontaneous erections are manageable. The effect peaks 2–4 hours post-injection and diminishes gradually over 8–12 hours.

Reduce the dose by 25–30% and administer with food or immediately after a light meal. Nausea is the most common adverse event with Melanotan-2 for erectile function, occurring in 35–60% of subjects depending on dose. It's mediated by melanocortin receptor activation in the area postrema—the brain's chemoreceptor trigger zone. The effect is dose-dependent and typically resolves within 2–4 hours. Taking the peptide with food slows absorption slightly but significantly reduces peak nausea intensity without compromising erectile response.

This dissociation suggests selective receptor activation, likely MC1R (responsible for melanogenesis and tanning) without sufficient MC4R occupancy. The dose required to activate MC4R is typically higher than the threshold for MC1R tanning effects, so subtherapeutic dosing is the most common explanation. If purity is verified and dosing is adequate (≥1mg per administration for most subjects), the issue may be individual variation in MC4R receptor density or signaling pathway integrity. Conditions that impair nitric oxide synthesis downstream of MC4R activation. Advanced diabetes, severe endothelial dysfunction, chronic PDE5 inhibitor use. Can blunt the erectile response even when receptor activation occurs. This is a known limitation: MT-2 initiates the NO synthesis cascade but cannot compensate for complete pathway failure at the guanylate cyclase or cGMP level.

Lyophilised MT-2 can tolerate ambient temperature (20–25°C) for 48–72 hours without catastrophic degradation, though this accelerates the degradation timeline. If unavoidable, pack the vial in an insulated container with ice packs to minimize temperature excursion. Once received, immediately transfer to −20°C storage. Reconstituted MT-2, however, cannot tolerate extended warm exposure: above 8°C for more than 12 hours, peptide bond hydrolysis accelerates significantly, and potency drops measurably. For transport of reconstituted peptides, use an insulin travel cooler designed to maintain 2–8°C for 24+ hours. If refrigeration is lost and the peptide has been at room temperature for more than 8 hours, assume partial degradation and adjust research protocols accordingly or discard the vial.